Alexandre de Streel

Alexandre de Streel is academic director of the digital research programme at the Brussels think-tank Centre on Regulation in Europe (CERRE), professor of European law at the University of Namur and visiting professor at the College of Europe (Bruges) and SciencesPo Paris. Besides, he chairs the expert group on the online platform economy advising the European Commission and is a part-time judge at the Belgian Competition Authority.

His main areas of research are regulation and competition policy in the digital economy as well as the legal issues raised by the developments of artificial intelligence.

Previously, Alexandre held visiting positions at New York University Law School, European University Institute in Florence, Barcelona Graduate School of Economics and University of Louvain. He also worked for the Belgian Deputy Prime Minister, the Belgian Permanent Representation to the European Union and the European Commission.

Dr. Walter C. Copan – Congressional Testimony: The State of U.S. Science and Technology: Ensuring U.S. Global Leadership

On February 5th, 2025, Dr. Walter C. Copan testified before the House Committee on Science, Space, and Technology on the State of U.S. Science and Technology: Ensuring U.S. Global Leadership. Copan, Vice President for Research and Technology Transfer at the Colorado School of Mines, former Director of the National Institute
Read More

(Transcript) Protecting Intellectual Property for National Security: A Conversation with Rep. Nathaniel Moran (R-TX)

This transcript is from a CSIS and LeadershIP event hosted on December 3, 2024. Watch the full video here. John J. Hamre: Good afternoon, everybody. Welcome. We’re delighted to have you here. My name is John Hamre. I’m the president at CSIS. And this is going to be one
Read More

Generic Drugs, Property Rights, and the Orange Book

By Chris Borges Intellectual property (IP) rights secured through patents facilitate the introduction of dozens of new brand-name drugs and hundreds of generic drugs annually in the United States. However, proposals advanced by the Biden administration have mistakenly singled out patents as the cause of high drug prices, potentially harming the dense networks
Read More